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sequence of immunosuppression, which has impli-
cations for all so-called nonpersistent pathogens. 
Previously, we observed prolonged and possibly 
chronic shedding of human metapneumovirus in 
two patients with cancer who were immunosup-
pressed because they were receiving chemother-
apy.2 Furthermore, it was recently reported that 
immunosuppression induced by lactate dehydro-
genase–elevating virus led to increases in the se-
verity and duration of the acute phase of friend 
virus infection in mice, most likely because of 
diminished CD8− responses.3 Such observations 
may provide support for earlier assumptions that 
if the CD4+ defense is insufficient because of im-
munosuppression, the CD8− response is unlikely 
to eliminate infection.4 The study by Kamar et al. 
revealed significantly reduced CD4− counts in pa-
tients with chronic HEV infection. Under these 
specific circumstances, so-called nonpersistent 
viruses may cause chronic colonization and re-
current infection. Hence, reducing drug-induced 
immunosuppression during acute HEV infection 
might be a strategy to prevent the progression to 
chronic hepatitis.
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The Authors Reply: With regard to the com-
ments by Schildgen et al., prolonged acute hepa-
titis A virus and HEV infections have been report-
ed previously in both immunocompromised and 
nonimmunocompromised patients.1,2 Our report 
indicated that HEV infection may evolve to chron-
ic hepatitis in organ-transplant recipients. In ad-
dition, a unique case of HEV-related cirrhosis has 
recently been reported.3 Schildgen et al. suggest 
that the evolution of HEV infection to chronic 
hepatitis is related to marked immunosuppres-
sion. They base their assumption on two studies 
of viral infections that appear to be unrelated to 
those that have been observed in organ-transplant 
recipients. We agree that the evolution of HEV in-
fection to chronic hepatitis in the setting of marked 
immunosuppression may be a mechanism, since 
we have found a lower CD4+ cell count in patients 
in whom chronic hepatitis evolved than in patients 
who were clear of the virus. Hence, in HEV-infected 
transplant recipients, we suggest reducing immu-
nosuppressive therapies that target T cells (i.e., 
mainly calcineurin inhibitors) in order to allow 
clearance of the virus.
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Phototherapy for Neonatal Jaundice
To the Editor: In their Clinical Therapeutics ar-
ticle on phototherapy for neonatal jaundice, Maisels 
and McDonagh (Feb. 28 issue)1 describe various 
mechanisms for maximizing the efficacy of pho-
totherapy. They state, “The dose and efficacy of 
phototherapy are also affected by the infant’s dis-
tance from the light (the nearer the light source, 
the greater the irradiance).” However, this state-
ment must be applied with great care. Indeed, 
guidelines from the American Academy of Pedi-
atrics Subcommittee on Hyperbilirubinemia spe-
cifically urge caution when halogen lamps, which 
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can generate significant amounts of heat, are used.2 
Placing these lamps as close as possible increases 
the risk of burns. Thus, physicians should be aware 
of this untoward side effect when positioning a 
halogen light to obtain maximum irradiance of a 
newborn with jaundice.
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To the Editor: In their review of phototherapy 
for neonatal jaundice, Maisels and McDonagh cite 
our work, suggesting that this form of therapy may 
influence the development of dysplastic nevi.1,2 
We have now investigated the prevalence of me-
lanocytic nevi among 11 monozygotic twin pairs 
1.
2.
in which one twin received phototherapy for neo-
natal jaundice and the other did not. Neonatal blue-
light phototherapy was associated with a consid-
erably higher number of common and clinically 
atypical nevi (Table 1). The increased number of 
nevi on persons receiving phototherapy might well 
be due to the effects of light on neonatal skin. 
Ultraviolet A light has profound immunosuppres-
sive effects and is sufficient to induce melanoma 
and melanoma precursors in animal models.3 
Moreover, visible light has also been shown to ex-
ert indirect DNA damage through the generation 
of reactive oxygen species.4 In view of the imma-
turity of the skin and immune system in newborns, 
intensive neonatal phototherapy could markedly 
influence melanocytes and nevus development.
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Table 1. Prevalence of Common and Clinically Atypical Melanocytic Nevi in 11 Monozygotic Twin Pairs in Which One 
Twin Received Neonatal Blue-Light Phototherapy (BLP) and the Other Twin Did Not.*
Twin Pair 
No. Sex Age
No. of Common  
Melanocytic Nevi
No. of Clinically Atypical 
Melanocytic Nevi
Total No. of  
Melanocytic Nevi
No BLP BLP No BLP BLP No BLP BLP
yr
1 M 6 0 3 0 0 0 3
2 F 8 1 4 0 0 1 4
3 M 11 4 17 1 3 5 20
4 F 14 26 28 0 5 26 33
5 M 14 12 27 2 4 14 31
6 M 18 3 3 0 1 3 4
7 M 20 11 12 0 1 11 13
8 F 23 21 15 1 3 22 18
9 M 24 8 9 0 1 8 10
10 F 24 9 27 0 3 9 30
11 M 30 3 12 3 13 6 25
P value 0.03 0.008 0.02
* Differences in the prevalence of common and clinically atypical melanocytic nevi between the exposed and nonex-
posed subjects were analyzed by means of a two-sided Wilcoxon signed-rank test (SPSS software, version 15.0). P val-
ues of less than 0.05 were considered to indicate statistical significance. Data concerning the neonatal history of the 
subjects were based on the official neonatal medical charts. A detailed standardized questionnaire was used to assess 
data concerning constitutional factors, sun exposure, and other variables; these factors proved to be very consistent 
in the examined twin pairs.
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To the Editor: The article by Maisels and Mc-
Donagh succinctly summarizes the mechanisms 
and application of phototherapy for jaundiced new-
borns. The authors promote the guidelines for 
using phototherapy that were published in 2004 
by the American Academy of Pediatrics,1 which are 
based primarily on total serum bilirubin levels. 
They admit that these guidelines are not evidence-
based, but rely primarily on expert opinion, and 
that “many infants are treated [2 to 3% of term 
or near-term infants and 150,000 to 250,000 pre-
mature infants each year] whose levels of total se-
rum bilirubin would not have reached the thresh-
old for exchange transfusion had phototherapy 
been withheld.”
The authors fail, however, to mention that theo-
retical considerations,2 substantial experimental 
data,3,4 and increasing evidence in human new-
borns5 all indicate that total serum bilirubin is a 
poor predictor of bilirubin-induced neurologic 
damage, whereas unbound (“free”) bilirubin lev-
els correlate well with neurotoxicity. Establishing 
evidence-based guidelines for phototherapy (and 
exchange transfusion), with the use of unbound 
(free) bilirubin measurements, could significantly 
improve selection and reduce the number of in-
fants requiring these treatments, as well as de-
crease hospital readmissions and the associated 
health care costs.
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The authors reply: Kapoor draws attention to 
an important issue. Halogen and tungsten lights 
should not be placed closer to the baby than rec-
ommended by the manufacturer because of the 
danger of a burn. We noted this in our article 
(Fig. 3 legend), and it is also a recommendation of 
the American Academy of Pediatrics guidelines.1
As noted by Csoma et al., the development of 
dysplastic nevi is a concern requiring further inves-
tigation. It is difficult to evaluate their findings 
because of a lack of information about the spec-
tral emission of the phototherapy lights, partic-
ularly their ultraviolet output; the distribution of 
the nevi; and the patients’ skin types. Properly 
shielded fluorescent lamps emit little radiation 
(<400 nm),2 and blue light-emitting-diode (LED) 
lights none at all. Although the findings in twin 
pairs might appear to be persuasive, the untreat-
ed twin is not an adequate control for the effects 
of phototherapy light on the treated twin. Proper 
sibling controls would need to be treated identi-
cally to their twins but not exposed to blue light 
or, alternatively, exposed to the same fixtures con-
taining lamps with only long-wavelength visible 
emission. In the absence of proper controls, the 
results reported could equally well be attributed, 
for example, to effects of electromagnetic-field 
radiation from the light-fixture ballasts as to ef-
fects of the phototherapy light. Reassuringly, to 
our knowledge, there are no reports of increased 
nevus formation in patients with the Crigler–Naj-
jar syndrome who have received daily photother-
apy since birth.
It is well known that the total bilirubin con-
centration alone is a poor predictor of kernicterus. 
Nevertheless, the risk of bilirubin encephalopathy 
increases with the bilirubin concentration at high 
bilirubin levels. Kernicterus in term and late-pre-
term infants is almost always associated with 
bilirubin concentrations higher than 25 mg per 
deciliter (428 μmol per liter) and rarely occurs at 
lower concentrations. Therefore, the total biliru-
bin concentration, which is readily measured, is 
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not to be ignored. The idea that unbound (“free”) 
bilirubin levels are useful in improving the selec-
tion of infants requiring treatment is a long-stand-
ing hypothesis that requires validation. Currently, 
such measurements are not offered by clinical 
laboratories in the United States, and there is con-
cern that bilirubin photoisomers may complicate 
their interpretation.3 Alternatives are the biliru-
bin:albumin molar ratio and the reserve bilirubin-
binding capacity of albumin in serum,4,5 which are 
more easily measured and might also facilitate 
identification of infants at greatest risk. Currently, 
attempts are being made to refine the American 
Academy of Pediatrics guidelines and reduce un-
necessary treatment.
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